Skip to main content
Genenta Science S.p.A. logo

Genenta Science S.p.A. - Investor Relations & Filings

Listed IPO Dec 2021
Ticker · GNTA ISIN · US36870W1009 LEI · 815600E860D130824E49 US Professional, scientific and technical activities
Open in API
Filings indexed 93 across all filing types
Latest filing 2026-07-14 Regulatory Filings
Country IT Italy
Listing US GNTA · 5 venues

Key figures FY2024

Period ended 2024-12-31 · EUR
Headline annual figures for Genenta Science S.p.A., fiscal year 2024, reported in EUR, with the source filing for each figure.
Net Income EUR -8.91M per the Annual Report filed 2025-03-28
Total Assets EUR 14.82M per the Annual Report filed 2025-03-28
Total Equity EUR 12.50M per the Annual Report filed 2025-03-28
Cash from Ops EUR -6.24M per the Annual Report filed 2025-03-28

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Genenta Science S.p.A.

https://www.genenta.com/

Genenta Science is a clinical-stage company developing immuno-oncology therapies based on a proprietary hematopoietic stem cell (HSC) gene therapy platform. The company's technology is designed to reprogram the tumor microenvironment, making solid tumors visible to the immune system and breaking immune tolerance. Its lead candidate, Temferon, aims to deliver therapeutics directly within the tumor mass. The treatment is being investigated as a potential one-time monotherapy and in combination with other approved therapeutics, such as immune checkpoint inhibitors. Clinical development includes a completed Phase 1 trial for Glioblastoma Multiforme and an ongoing Phase 1/2a study in metastatic Renal Cell Carcinoma.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed with the SEC by Genenta Science S.p.A. It provides an update on ongoing legal proceedings regarding a challenge to shareholder resolutions and the subsequent court order revoking a suspension of a corporate purpose amendment. As Form 6-K is a general regulatory filing used by foreign private issuers to disclose material events that are not specifically covered by other categories (like earnings or dividends), and this document specifically details legal developments, it falls under the RNS (Regulatory Filings) category.
2026-07-14 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K report filed by a foreign private issuer, Genenta Science S.p.A., with the U.S. SEC. It primarily describes the outcomes of the June 2026 Annual Shareholders' Meeting where key approvals were made including the statutory financial statements, appointment of directors, and authorization for treasury shares. It also provides an update on a financing transaction completion. There is no full set of financial statements or detailed financial performance analysis typical of annual or interim reports. The filing is a report of material corporate events and updates commonly reported on Form 6-K, which corresponds to miscellaneous regulatory filings from foreign issuers. The content fits best with Regulatory Filings (RNS) as it provides corporate event updates without being a full financial report, certification, or other narrowly defined filing type under the given categories.
2026-07-01 English
6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filing by Genenta Science S.p.A., a foreign private issuer, submitted to the SEC. Form 6-K is used for current reports by foreign private issuers to announce material events that occur between their annual reports. The text reports legal updates regarding court rulings on shareholder resolutions, specifically about multiple voting rights and amendment to the corporate purpose. The document does not contain financial statements or detailed financial information but provides a regulatory/legal event update. There is also a forward-looking statement disclaimer, typical in regulatory filings. Thus, the best classification is Regulatory Filings (RNS), which serves as the fallback for miscellaneous important disclosures by companies that do not fit other categories like annual reports, earnings releases, or management reports.
2026-06-26 English
6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Genenta Science S.p.A., reporting on other events specifically concerning a severance agreement and an amendment to a non-compete covenant for the CEO. It includes the text of agreements as exhibits and is in compliance with Securities Exchange Act. It is not an annual or interim report, not a financial statement release, but rather an update on changes in management agreements and related contractual arrangements. This falls under the category for announcements related to changes or events involving senior management or board. Given the focus on a severance and amendment in employment terms related to the CEO, the best suited classification is Board/Management Information (MANG). The document length is about 4100 characters, which aligns with a typical filing of this type, and it is not a mere report publication announcement (RPA) because it includes substantive descriptions and exhibits rather than just announcing availability of a report. Therefore, classification code is MANG with high confidence.
2026-06-24 English
6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Genenta Science S.p.A., providing an announcement about the upcoming Ordinary and Extraordinary Shareholders' Meeting. It includes details about the meeting notice, agenda items such as shareholder approvals, board appointments, and capital changes, but does not contain detailed financial statements or the full report itself. The document references a Notice of Meeting (Exhibit 99.1) and where further materials can be found, indicating it is primarily an announcement of a shareholders' meeting and associated materials rather than the full report. The Notice includes voting matters and shareholder meeting information but does not present voting results or detailed executive changes. Given the content and format, it most closely corresponds to a Proxy Solicitation & Information Statement category (PSI), which typically includes materials informing shareholders about meetings and soliciting votes. It is not an AGM Information (AGM-R) since it is not simply presentation material, and not a Declaration of Voting Results (DVA) since results are not included.
2026-06-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is used by foreign private issuers to provide material information to the U.S. SEC between annual reports. The content is an update notifying the company has regained compliance with the Nasdaq minimum bid price rule, specifically citing Nasdaq Listing Rule 5550(a)(2). It is an event update rather than a financial report or earnings release. There is no detailed financial data or management discussion included, and the document length is only 2856 characters, indicating a brief announcement. Thus, it is best classified under Regulatory Filings (RNS), the fallback category for such announcements and regulatory updates that do not fit other specific report types.
2026-06-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.